You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0527 Lesinurad, A Selective Uric Acid Reabsorption Inhibitor, in Combination with Xanthane Oxidase Inhibitors: SUA and Flares Composite Endpoint from Phase III Studies in Gout Patients (Clear 1, Clear 2 and Crystal)

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
THU0527 Lesinurad, A Selective Uric Acid Reabsorption Inhibitor, in Combination with Xanthane Oxidase Inhibitors: SUA and Flares Composite Endpoint from Phase III Studies in Gout Patients (Clear 1, Clear 2 and Crystal)

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016501
Aug 20162803
Sep 20162004
Oct 20162604
Nov 20162803
Dec 20161201
Jan 20172503
Feb 20171200
Mar 20172602
Apr 20171300
May 20175109
Jun 2017500
Jul 20173801
Aug 20172002
Sep 20174200
Oct 20172201
Nov 20171802
Dec 20172000
Jan 20186002
Feb 20182602
Mar 20183401
Apr 20182400
May 20181801
Jun 20183800
Jul 20182200
Aug 20181000
Sep 20181000
Oct 20181000
Nov 20181600
Dec 20181600
Jan 20191000
Feb 20191400
Mar 2019800
Apr 2019200
May 2019200
Jun 2019400
Jul 2019200
Sep 2019800
Nov 2019400
Dec 2019400
Jan 2020200
Feb 2020200
Apr 2020200
May 2020200
Jun 2020400
Jul 2020400
Aug 2020601
Sep 20201600
Oct 20201200
Nov 2020400
Dec 2020600
Jan 20211400
Apr 20211001
Jun 2021003
Oct 2021600
Nov 2021400
Dec 20211600
Feb 2022200
Mar 2022800
Apr 2022500
May 2022800
Jun 2022200
Jul 2022400
Aug 2022600
Sep 20221200
Oct 2022800
Nov 2022600
Dec 2022800
Jan 2023800
Feb 2023400
Mar 2023800
Apr 2023400
May 2023600
Jun 2023200
Jul 2023200
Aug 2023600
Sep 2023800
Nov 2023200
Dec 20234400
Jan 2024200
Feb 2024800
Mar 2024200
Total1038047